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1. Summary
Fusidic acid (FA) is a bacteriostatic antibiotic that locks elongation factor G
(EF-G) to the ribosome after GTP hydrolysis during elongation and ribosome
recycling. The plasmid pUB101-encoded protein FusB causes FA resistance in
clinical isolates of Staphylococcus aureus through an interaction with EF-G.
Here, we report 1.6 and 2.3 A ˚ crystal structures of FusB. We show that
FusB is a two-domain protein lacking homology to known structures, where
the N-terminal domain is a four-helix bundle and the C-terminal domain
has an alpha/beta fold containing a C4 treble clef zinc finger motif and two
loop regions with conserved basic residues. Using hybrid constructs between
S. aureus EF-G that binds to FusB and Escherichia coli EF-G that does not, we
show that the sequence determinants for FusB recognition reside in domain
IV and involve the C-terminal helix of S. aureus EF-G. Further, using kinetic
assays in a reconstituted translation system, we demonstrate that FusB can
rescue FA inhibition of tRNA translocation as well as ribosome recycling. We
propose that FusB rescues S. aureus from FA inhibition by preventing formation
or facilitating dissociation of the FA-locked EF-G–ribosome complex.
2. Introduction
Fusidic acid (FA) is a bacteriostatic antibiotic that was first isolated from the
fungus Fusidium coccineum in the early 1960s [1]. FA blocks bacterial protein
synthesis by locking elongation factor G (EF-G) to the ribosome [2]. Clinically,
FA is mainly used against staphylococcal infections, often in combination with
other drugs to prevent resistance development.
EF-G is a translational GTPase catalysing two different steps of protein syn-
thesis (reviewed by Schmeing & Ramakrishnan [3]). First, EF-G is needed for
translocation of tRNAs and mRNA with respect to the ribosomal 30S subunit
to make a new mRNA codon available for decoding. Second, EF-G acts together
with ribosome recycling factor (RRF) in splitting of the ribosomal post-
termination complex. In both of these steps, GTP hydrolysis by EF-G is used
as an energy source, and in both cases FA prevents the release of EF-G from
& 2012 The Authors. Published by the Royal Society under the terms of the Creative Commons Attribution
License http://creativecommons.org/licenses/by/3.0/, which permits unrestricted use, provided the original
author and source are credited.the ribosome after GTP hydrolysis [2,4]. Since FA locks EF-G
in a defined state with GDP on the ribosome, the drug has
also been used as a tool in structural studies of ribosome–
EF-G complexes by cryo-electron microscopy and crystallo-
graphy [5–7]. These structures display EF-G conformations
that are similar to what is observed in a complex blocked
with a non-hydrolysable GTP analogue [8]. In contrast, the
observed EF-G conformations are distinctly different from
isolated crystal structures of EF-G in apo form [9,10] with
GDP [11,12] or with a GTP analogue [13]. Most of these struc-
tures are of Thermus thermophilus EF-G and are in similar
global conformations, probably owing to crystal packing.
The main conformational change in EF-G occurs between
two blocks of the structure, consisting of domains I–II and
domains III–V, and is triggered by a combination of ribo-
some interactions and conformational changes of the two
switch regions upon GTP hydrolysis.
The FA binding site was for the first time visualized
in the FA-locked 3.6 A ˚ crystal structure of EF-G with the
70S ribosome [6]. FA binds at the interface between domains
I, II and III of EF-G, and only displays high affinity to the
ribosome-bound EF-G. The structure clarified that the drug
locks EF-G in a conformation between the ribosome-binding
GTP state and the dissociating GDP state [6]. Specifically,
FA binds to EF-G after GTP hydrolysis, when the switch I
region has left its ordered GTP conformation and prevents
switch II from leaving its GTP-like conformation. Thereby,
the drug stops the conformational change of EF-G that is
presumably needed for dissociation from the ribosome.
A recent study shows that the recycling step in vitro is inhib-
ited at more than 1000-fold lower FA concentration than the
translocation reaction [14]. However, it remains unknown
whether either or both of these steps are the natural targets
of FA in vivo.
It was recognized early that FA resistance could reside in
EF-G [15]. To date, the identified types of FA resistance are
defined as fusA, fusB, fusC, fusD and fusE (reviewed by Farrell
et al. [16]). Mutations in the drug target, EF-G, belong to
the fusA class [17,18]. While some of these directly affect
the FA-binding site [6], others perturb EF-G–ribosome con-
tacts, conformational dynamics of EF-G or the stability of
EF-G domains [10,12,19], reflecting that FA only binds to a
defined conformation of EF-G on the ribosome. The fusE
mutants have frameshift or truncation mutations in the rplF
gene encoding ribosomal protein L6 [18]. These in vitro-
selected mutants are the only known ribosomal FA resistance
mutations and affect a contact area with EF-G [6,10].
Plasmid-based resistance towards FA in S. aureus was first
demonstrated nearly four decades ago [20,21], but it was only
more recently that the resistance-causing gene fusB was
identified on the 22 kB pUB101 plasmid [22,23]. FusB is a
25 kD protein that can provide low-level FA resistance in
S. aureus [22,23]. It displays sequence homology to a Listeria
monocytogenes fibronectin-binding protein [22,23] implicated
in host-cell attachment [24], but does not bind to fibronectin
[23]. FusB does not display sequence homology to any
protein of known three-dimensional structure and its evol-
utionary origin remains to be analysed. The chromosomally
encoded FusB homologue FusC exists in some S. aureus
strains [25], and FusD has been found to cause the inherent
resistance of Staphylococcus saprophyticus [25]. Recent studies
indicate that fusB and fusC are the most common types of
FA resistance in recent clinical isolates of methicillin-sensitive
S. aureus, while fusA is more common in methicillin-resistant
S. aureus [25,26].
In pull-down experiments, His-tagged FusB pulled out
one single protein, identified as EF-G, from S. aureus cell
extract, while no protein was pulled out from E. coli extract.
Since FusB could protect an S. aureus-based in vitro trans-
lation system from FA inhibition, but failed to do the same
to an E. coli-based system, it was concluded that the inter-
action between FusB and EF-G is crucial for the FusB
resistance mechanism [23].
Beyond that, the mechanism of action of FusB is
unknown. In this study, we have solved the crystal structure
of FusB, mapped its binding site on EF-G and demonstrated
that FusB can rescue FA inhibition in elongation as well as in
recycling. We conclude that FusB provides FA resistance by
preventing formation or facilitating dissociation of the FA-
locked EF-G–ribosome complex in both of these steps.
3. Results
3.1. Structure determination of FusB
An N-terminally His-tagged version of FusB was cloned
from plasmid pUB101 present in clinical isolates of S.
aureus [21] and overexpressed in E. coli. FusB was crystallized
under several different conditions at the high-throughput
crystallization facility in Grenoble, France. After optimiz-
ation, crystals in space group P21212 diffracting to 1.6 A ˚
resolution grew in polyethylene glycol at pH 5.5, and crystals
in space group P1 diffracting to 2.3 A ˚ resolution grew in poly-
ethylene glycol at pH 8.1. The structure was solved using
single-wavelength anomalous dispersion with P21212 crystals
soaked in sodium iodide and refined against the native data.
The P1 crystal structure was solved by molecular replacement
using the refined P21212 FusB structure as search model. FusB
crystallized as a dimer in the asymmetric unit of both crystal
forms. The A molecule of the P21212 structure was fully
ordered apart from the His-tag, whereas the other molecules
displayed disorder in one or several loop regions. In the
P21212 structure, we observed a continuous density across
the domain interface between residues Ser15, Lys162 and
Thr200 that we failed to interpret (electronic supplementary
material, figure S1). Attempts to identify any bound ligand
by mass spectrometry failed. Below, unless stated otherwise,
the higher-resolution P21212 structure will be described.
3.2. Overall structure
The FusB structure consists of two domains, together forming
a structure of approximately 70   37   30 A ˚ size. The N-
terminal domain is an elongated up–down four-helix
bundle, while the C-terminal domain is a more spherical
alpha/beta domain stabilized by a zinc ion (figure 1a,b).
3.3. Sequence analysis of Staphylococcus aureus FusB
Staphylococcus aureus FusB displayed significant sequence hom-
ology to about 170 other protein sequences, the majority from
bacilli and enterococci, found in a BLAST search (data not
shown). Out of these, we chose to align the S. aureus FusB
sequence to a subset of nine sequences with experimental evi-
dence for a role in FA resistance or for inherent FA resistance
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2of the respective species (figure 1c; references in figure legend).
The Staphylococcus haemolyticusprotein is atruncated versionof
FusB,andtheothersequencesdisplay30to46percentsequence
identity to FusB (the Lactobacillus plantarum protein being least
similar). The resulting sequence alignment allowed mapping
of the conserved residues on the FusB structure (figure 1d,e).
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Figure 1. Overall structure of FusB. (a) Cartoon diagram of the FusB structure. Domain I is shown in blue and domain II in yellow and red. (b) Topology of FusB.
Colours as in (a). (c) Sequence alignment of FusB with homologues having experimental evidence for FA resistance (reference after each accession code). S. aureus
FusB: NP_932197.1 [22,23], S. aureus FusC: YP_042173.1 [25], S. saprophyticus FusD: YP_302255.1 [25], S. haemolyticus FusB: CAJ43426.1 [27], E. faecalis T11
fibronectin-binding protein: ZP_05595118.1 [28], E. faecium D344SRF fibronectin-binding protein: ZP_06447277.1 [28], L. plantarum fibronectin-binding protein:
CCC77620.1 [29], L. innocua putative fibronectin-binding protein: NP_470072.1 [23], L. monocytogenes str. 1/2a F6854 fibronectin-binding protein: ZP_00232898.1
[30], L. welshimeri fibronectin-binding protein: YP_848891.1 [30]. The secondary structure is indicated on top, conserved residues are marked in orange,
conservatively substituted residues in yellow and conserved zinc ligands in green. Stars indicate surface-exposed conservations. (d) Location of conserved residues in
the FusB structure. Conserved and conservatively substituted residues are shown as sticks. (e) Sequence conservation mapped on the FusB surface. Conserved residues
are shown in orange and conservatively substituted residues in yellow. The four views are 908 apart and the first two correspond to the ones in (a).
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3In the N-terminal domain, most of the conserved residues are
partofthehydrophobiccore,andonlytwosurface-exposedresi-
duesAsn28andAsp29atthetipofthedomainareconserved.In
contrast, the C-terminal domain, as discussed below, contains
several patches with exposed conserved residues.
3.4. C-terminal domain
The C-terminal domain as a whole has a novel fold that is not
present in any other structure in the protein data bank (PDB),
assessed using the Dali and VAST servers. After an inter-
domain linker, the domain starts with a short helix H5 and a
long loop. The helix and the loop contain seven lysine residues
from amino acids 93 to 105. Four of these—Lys99, Lys101,
Lys102 and Lys104—are strictly conserved in the aligned
FusB homologues (figure 1c,d). All the lysines in the helix
and the loop are pointing outwards from the protein, repelling
each other. The B-factors of the loop are above average, but the
hydrophobic residues of the loop (Phe98, Val101, Ile104) par-
ticipate in the hydrophobic core and keep the backbone
conformation similar in all four FusB molecules.
After another short helix, the domain continues in five-
stranded anti-parallel beta sheet, forming a jaw-like structure
biting into a V-shape of two short helices. The first part of the
beta sheet formed by S1, S2 and the N-terminal part of S3 is
rather flat, while the second part involving S3, S4 and S5
is curved and twisted. In the loop between S1 and S2,
there is a short 3
10 helix H7. The long strand S3 contains a
beta bulge, in which, between the amides of residues 149
and 153, three amino acids are outside the sheet, opposite
to residue 167 in S4. This contributes to the sharp curvature
of the sheet that is also stabilized by a zinc ion at the tip
of the loop between S3 and S4. The last beta hairpin S4–S5
extends in the same direction as the lysine-rich loop, ordered
by a crystal contact with the N-terminal domain of a sym-
metry-related molecule, but is disordered in three of the
FusB copies. The C-terminus of FusB forms two helices
H8–H9 in a 508 V-shape enclosed by the beta sheet. The
domain contains a number of exposed conserved residues,
mostly at the far end of the molecule.
Beta strands S3–S5 form a non-canonical treble-clef zinc
finger motif [31] (figure 2a,b), where, in this case, a zinc ion is
coordinated by four strictly conserved cysteine residues in a
CXXC-X23-CX5C motif (figure 1c). Out of the four zinc-coordi-
nating residues, two are located in the loop between S3 and S4
(the so-called zinc knuckle), one at the end of S5 and one in H8.
Thezincsiteformsasmallandrigidcorethatstabilizestheoverall
structure of the C-terminal domain and the interface to the N-
terminal domain. The orientation between the secondary struc-
ture elements is different when compared with the standard
motif, exemplified with ribosomal protein L24e (figure 2c), as
the polypeptide before the zinc knuckle forms a beta strand in
the same sheet as the beta hairpin between the second and
third cysteine. Additionally, the space between the two last
cysteines is larger than the usual two to three amino acids.
3.5. Structural comparison
The two molecules in the P21212 crystal form superpose with a
root-mean-square deviation (RMSD) of 0.41 A ˚ for 200 CA
atoms while the two molecules in the P1 crystal form super-
pose with an RMSD of 0.49 for 197 CA atoms. When all four
molecules were overlaid based on the C-terminal domain
(residues 1–81), a minor rotational movement of the
C-terminaldomain could be visualized (electronic supplemen-
tary material, figure S2a). The maximum shift is 2.4 A ˚ in the
positionoftheH7helixbetweenmoleculeA intheP21212crys-
tal form and molecule B in the P1 crystal form. One possible
reason for the lack of conformational differences between the
twocrystalforms isthehighsimilarityincrystalcontactsinvol-
ving the inside and outside of the domain border (electronic
S3
(a)
(b)
(c)
S2
S1
S5
S4
C189
C157
C195
C160
H8
H7
Figure 2. Structure of the FusB zinc site. (a) Structure of the FusB treble-clef
zinc finger. Residues 127–208 are included, Zn is shown in grey and the four
Cys ligands are shown as sticks. (b) Structure of the zinc site. The final 2Fo-Fc
map is contoured at 2.0 sigma (grey) and the anomalous difference map
from a dataset at 1.278 A ˚ wavelength is contoured at 4.0 sigma (magenta).
Water is shown in red and sodium in purple. (c) Structure of ribosomal
protein L24e including a standard treble-clef zinc finger (pdb 1vq8 [32]).
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4supplementary material, figure S3). The interface between the
two domains is partly hydrophobic (electronic supplementary
material, figure S2b) and trialsto expressthe two domains sep-
arately failed, suggesting that the domains are not soluble as
separate entities.
The region 172–185 has different conformations in the
two molecules in the asymmetric unit. In the first molecule
it is a perfect beta hairpin; in the other molecule, the two
strands are separated from each other, so that Ala 188 has
moved by 9.7 A ˚ and residues 182–186 are disordered
(electronic supplementary material, figure S2a).
3.6. Mapping of the FusB binding site on elongation
factor G
FusB has previously been shown to form a complex with EF-
Gf r o mS. aureus, but not with EF-G from E. coli [23]. Since
these two EF-Gs share a sequence identity of 60 per cent
and S. aureus EF-G is active in translation with E. coli ribo-
somes (see below), we decided to map the FusB binding
site on EF-G using hybrid constructs, where some of the
five domains were from S. aureus EF-G (figure 3a) and the
rest from E. coli EF-G. Initially, four such constructs were
made with either domains I and II from one species and
domains III–V from the other species, or domains I–III
from one species and domains IV and V from the other
species (hybrids A–D, figure 3b). Wild-type and hybrid EF-
Gs were tested for binding to FusB using size-exclusion
chromatography. Because of the small difference in molecular
weight of the EF-Gs and FusB–EF-G complexes (82–88 and
108–114 kDa, respectively), the experiments were performed
with twofold excess of FusB so that the shift in elution
volume of the EF-G peak could be used as a read-out of
FusB binding. The shift in elution volume agrees with the
increase in molecular mass upon formation of a 1:1 complex
(a) (b)
(c)( d)( e)
(f)( g)( h)
(i)( j)( k)
S. aureus 
E. coli 
hybrid A
hybrid B
hybrid C
hybrid D
hybrid E
hybrid F
hybrid G
I
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V
V
0 51 0 1 5 2 5 20
V (ml)
0 51 0 1 5 2 5 20
V (ml)
0 51 0 1 5 2 5 20
V (ml)
O
D
2
8
0
O
D
2
8
0
O
D
2
8
0
S. aureus E. coli  hybrid A
hybrid B hybrid C hybrid D
hybrid E hybrid F hybrid G
Figure 3. Mapping of determinants for FusB recognition of S. aureus EF-G. (a) Structure of S. aureus EF-G (pdb 2xex [10]) with domains indicated in different
colours and by roman numerals. (b) EF-G constructs used in gel-filtration binding assays. Domains are coloured as in (a) and striped areas indicate E. coli sequence
(remaining parts have S. aureus sequence). (c)–(k) Gel-filtration chromatograms of all EF-G constructs in (b) (dotted lines) and the same constructs in the presence
of twofold excess of FusB (solid lines) on HiLoad 10/300 Superdex200. (k) Upper dotted line includes 2.5-fold excess of FusB.
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5of EF-G and FusB. The large difference in height of EF-G
peaks relative to FusB is explained by the different number
of aromatic residues in the two EF-Gs leading to a 22 per
cent higher theoretical extinction coefficient for E. coli EF-G.
Size-exclusion chromatographyshowed that FusB formed a
complex with S. aureus EF-G as well as with hybrids B and D,
where domains IV and V had S. aureus sequence (figure 3c–h).
Further binding tests with hybrids E and F where only
domain IV or domain V had S. aureus sequence (figure 3b)
showed that domain IV contained the sequence determinants
necessary and sufficient for FusB binding (figure 3i,j).
Finally, in hybrid G, we mutated the C-terminal helix of
hybrid E (part of domain IV, but after domain V in the
sequence; figure 3a,b)b a c kt oE. coli sequence. This construct
displayed partial binding to FusB (figure 3k), indicating that
this helix constituted part of the FusB binding site. To
check that this construct was not partially misfolded, we
also tested a higher FusB concentration and confirmed that
EF-G could be saturated with FusB.
3.7. FusB-mediated rescue of fusidic acid inhibition in a
reconstituted transcription–translation system
We used a reconstituted transcription–translation system
made up of purified translation components from E. coli [33]
producing firefly luciferase to study the effect of FA and
FusB in the EF-G-mediated steps of translation. Synthesis of
luciferase was followed in a GloMax 20/20 luminometer for
1 h and the amount of active protein produced was estimated
in luminescence units. The luciferase construct contained 593
amino acids and successful production thus required 592
translocation events. To allow only single-round luciferase
synthesis, RRF was omitted from the reaction mixture. Staphy-
lococcus aureus EF-G showed successful synthesis of luciferase
with or without ribosome recycling (figure 4a, no FA), with
approximately half the yield compared with E. coli EF-G
(data not shown), demonstrating its compatibility with an E.
coli-based translation system. The luciferase yield gradually
decreased with increasing concentration of FA (figure 4a).
Interestingly, the reaction was inhibited more efficiently
including ribosome recycling than without (75% and 60%
inhibition, respectively) at an FA concentration of 10 mM.
We tested the effect of FusB on FA inhibition in multiple-
and single-round luciferase synthesis with S. aureus EF-G
(figure 4b). In the former reaction, EF-G drove both elongation
and recycling, whereas in the latter case ribosome recycling
was excluded. Addition of FusB increased both multiple- and
single-round luciferase synthesis (figure 4b) up to four- to five-
fold when compared with the reactions with only FA. Thus,
these experiments demonstrated that FusB could provide FA
resistance in elongation as well as in ribosome recycling. FusB
could not rescue FA inhibition of luciferase synthesis with an
identical system including E. coli EF-G (figure 4c), in line with
a previous report [23]. However, as shown in figure 4b,c,t h e
activity of FusB was not dependent on the origin of any other
translational component except S. aureus EF-G.
3.8. FusB-mediated rescue of fusidic acid inhibition of a
single elongation step
We have tested the effect of FusB on a tripeptide formation
assay using S. aureus EF-G. The reaction was quenched in
10s, which was long enough for the completion of a single
elongation step, but too short for multiple rounds. FA
(150 mM) inhibited tripeptide formation to 50 per cent, and
in the presence of 1 mM FusB the extent of tripeptide for-
mation recovered to approximately 75 per cent (figure 5a).
FusB alone at the same concentration did not influence the
yield. The observed rescue was specific to S. aureus EF-G,
as no rescue occurred with E. coli EF-G (data not shown).
These results confirmed that FusB rescued EF-G function
from FA inhibition in the peptide elongation step.
3.9. FusB-mediated rescue of fusidic acid inhibition of
ribosome recycling
Splitting of a post-termination complex by EF-G and RRF
was monitored in a stopped-flow instrument with Rayleigh
light scattering, where the smaller size of the ribosomal
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Figure 4. FusB action on FA-inhibited elongation and ribosome recycling.
(a) The effect of FA (0–50 mM) on luciferase synthesis in a reconstituted
transcription–translation system in the presence (blue bars) or absence (red
bars) of RRF. EF-G was from S. aureus and all other components were from
E. coli. (b) The effect of FusB (1 mM) on multiple round luciferase synthesis
(with RRF, blue bars) or single round luciferase synthesis (without RRF, red
bars) in the absence and presence of FA (20 mM). (c) The effect of FusB
(1 mM) on multiple round luciferase synthesis using E. coli EF-G in the
absence and presence of FA (20 mM).
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6subunits compared with 70S leads to a decrease in light
scattering. Staphylococcus aureus EF-G, together with E. coli
RRF, could successfully split E. coli 70S at a rate of 0.15 s
21
(figure 5b). The splitting reaction was completely blocked
with 10 mM FA and no reaction was observed even at
longer incubation. When FusB (1 mM) was added to the
FA-inhibited reaction, ribosome splitting could occur again,
although at a lower rate (0.02 s
21), demonstrating that FusB
could rescue FA-mediated inhibition of ribosome splitting
driven by EF-G and RRF.
4. Discussion
4.1. FusB structure
We have solved the crystal structure of FusB in two different
crystal forms at different pH. The structure has two domains,
where the N-terminal four-helix bundle is a common fold
that occurs in proteins with many different functions. It
provides a rigid structure stabilized by a tightly packed
hydrophobic core in combination with salt bridges and
hydrogen bonds between neighbouring helices.
The C-terminal domain has a unique fold stabilized by a
treble-clef-like zinc finger motif. These motifs display limited
sequence similarity and occur in proteins involved in various
functions, but often interacting with nucleic acids [31]. Apart
from the zinc site, FusB does not display significant similarity
to any other protein of this class.
After submission of the present work, we became aware
of a very recent paper describing the crystal structure of the
FusB homologue FusC (42% sequence identity to FusB;
figure 1c) and the biochemical characterization of how FusB
acts on non-programmed ribosome complexes with and
without FA [34]. The crystal structure of FusC (pdb 2yb5)
is very similar to the structures of FusB. The entire structure
superimposes with RMSD of 1.4 A ˚ (for 194 CA atoms) or
less onto any of the four FusB structures. When the FusB
and FusC structures are superimposed based on domain I,
there is a 2.2 A ˚ shift of the Zn ion (electronic supplementary
material, figure S2c).
FusB binds with high affinity to EF-G and also has pro-
pensity to bind nucleic acids, as observed during
purification. Analysis of the sequence conservation mapped
on the structure (figure 1c–e) suggests that both of these
binding activities are likely to reside in the C-terminal
domain. The exposed conserved residues in the C-terminal
domain cluster in three regions—the H5–H6, S1–S2 and
S4–S5 loops—all located at the far end of FusB (figure 1c–
e) and potentially contributing to the same macromolecular
binding site. Secondary structure prediction suggested the
H5 helix would continue until residue 102, including most
of the Lys residues that now project away from each other.
A longer helix may form upon interaction with a negatively
charged binding partner, and this may lead to a shift in the
position of H5 with respect to S2 and S3 or induce an inter-
domain movement. We observe different conformations of
the S4–S5 loop, but no major inter-domain movements
between the two crystal forms; however, we cannot exclude
that larger changes would occur upon binding to, for
example, EF-G.
The function of nucleic acid binding by FusB is unknown,
but two possibilities are an interaction with the ribosome or
involvement in the regulation of its own synthesis. FusB is
induced by translational attenuation based on an alternative
mRNA structure that is formed only when ribosomes are
stalled on the fusB leader sequence during FA inhibition [23].
Additional candidate EF-G-binding regions are the two
sides of the inter-domain interface that demonstrate their
protein-binding propensity in crystal packing, and where
we observe an unknown density (electronic supplementary
material, figure S1). To create specific protein–protein bind-
ing, a binding surface around 1000 A ˚ 2 is normally needed
[35], and the crystal packing interactions involve approxi-
mately this area. In the recent paper by Cox et al., the EF-G
binding site on FusB was mapped through nuclear magnetic
resonance (NMR) chemical shift mapping of backbone
amides, showing that EF-G probably binds to the beta strands
S3, S4 and S5 [34] (upper part of beta sheet in figure 1a, top).
Part of this surface is involved in forming the ‘hugging’
dimer that we observe in crystal packing (electronic sup-
plementary material, figure S3). However, since the loop
regions H5–H6, S1–S2 and S4–S5 at the far end of the mol-
ecule were not assigned in the NMR experiment, it does not
provide any data regarding their potential involvement in
EF-G binding [34]. Interestingly, there were also chemical
shift differences in the inter-domain linker that could be a
sign of inter-domain movement.
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Figure 5. The effect of FA and FusB on tripeptide formation and ribosome
recycling. (a) Tripeptide formation was initiated by mixing IM and EM
containing S. aureus EF-G (see §5.10 for details). The fraction of mono- (fMet,
red bars), di- (Met-Phe, green bars) and tri- (Met-Phe-Phe, purple bars)
peptide formed in 10 s without (control) or with different combinations of FA
(150 mM) and FusB are presented as indicated below the bars. (b) Splitting
of a post-termination complex (0.5 mM) (programmed with MFF-stop
mRNA) was followed by decrease in Rayleigh light scattering by mixing with
RRF (10 mM), and S. aureus EF-G (5 mM) in the stopped flow without FA
and FusB (trace 1), with FA (10 mM) alone (trace 2) or with FA (10 mM) and
FusB (1 mM) (trace 3).
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74.2. Staphylococcus aureus elongation factor G works
with Escherichia coli translation components
Gram-positive S. aureus is distantly related to gram-negative
E. coli. Our biochemical experiments show that S. aureus
EF-G can still function with E. coli ribosomes in vitro. The
60 per cent sequence identity between EF-G from these two
species must preserve functionally critical interactions
between EF-G and the ribosome. Also, even though FusB
binding and rescue are specific to S. aureus EF-G, FusB can
exhibit its protective activity when all other components are
from E. coli (figure 4c).
4.3. FusB acts in elongation and recycling
GTP hydrolysis by EF-G is used to drive elongation as well as
ribosome recycling together with RRF. FA acts by inhibiting
the release of EF-G.GDP from the ribosome in both of these
steps. It was shown that FA inhibits ribosome recycling
more effectively than elongation [14]. Similarly, in our
experiments (figure 5), FA inhibition of recycling occurs at
a lower drug concentration than elongation, although the
difference in the FA concentration was smaller than reported
earlier. Also, in the reconstituted transcription–translation
system with more than 500 rounds of elongation and one
round of ribosome splitting per luciferase molecule, there is
a notable difference in inhibition with and without RRF
(figure 4b,c).
It is an open question whether FusB would rescue either
or both of the steps involving EF-G. The only previous
information available regarding FusB activity was from
experiments conducted in a staphylococcal S30 extract [23].
Our experiments with S. aureus EF-G in a reconstituted tran-
scription–translation system (E. coli) enabled us to test its
function with or without ribosome recycling. FusB recovered
luciferase synthesis from FA inhibition in the presence as well
as in the absence of RRF (figure 4b). These results were
further confirmed by fast kinetic measurements of elongation
and ribosome splitting under single turnover conditions,
where FusB rescued both reactions fully or partially from
FA inhibition (figure 5a,b). Thus, we demonstrate for the
first time that FusB rescues the translation system from FA
inhibition in both the elongation and recycling steps, repre-
senting EF-G locked to ribosomes in classical and ratcheted
states, respectively [14].
4.4. FusB binding site on elongation factor G:
implications for function
We have located the determinants for FusB binding of S.
aureus EF-G to domain IV and showed that the terminal
helix of EF-G forms a part of this binding site. However,
we cannot exclude that FusB might make additional inter-
actions with other parts of EF-G that are conserved
between S. aureus and E. coli. In any case, as judged by
size-exclusion chromatography, a hybrid construct contain-
ing domain IV of S. aureus EF-G and the remaining
sequence from E. coli shows the same degree of complex
formation with FusB as the wt S. aureus EF-G. We estimate
that Kd for the FusB–EF-G complex is in the low micro-
molar range, or lower, and we fail to detect any difference
in affinity between FusB and EF-G in the presence of GDP,
GTP or FA (data not shown). To gain further informa-
tion regarding the interactions, we would need to check the
affinity using other methods such as Biacore or ITC. Cox
et al. [34] have determined the affinity between FusB and
EF-G, as well as FusB and domains III–V of EF-G, to
60 nM using ITC.
Domain IV of EF-G is composed of two segments: residue
481–603 and the C-terminal helix 675–693 (S. aureus number-
ing). The terminal helix makes contact with domain IV as
well as domain V, and accommodates to maintain both inter-
actions when EF-G changes its conformation, as judged by
comparing crystal structures of T. thermophilus EF-G in
isolation [12] and on the ribosome locked with FA [6].
The difference in FusB binding by EF-G hybrids E and G
(figure 3) could be owing to surface properties of the helix
or interactions of the terminal helix with domains IV and V
that disturb binding of FusB, but shows that the helix directly
or indirectly is important for the interaction of FusB with
S. aureus EF-G.
4.5. Relevant mechanisms of antibiotic resistance
There are four common mechanisms of antibiotic resistance.
The first one is active efflux involving, for example, multi-
drug resistance transporters or decreased drug uptake. The
second one is modification of the drug target (e.g. the point
mutations of residues in EF-G that directly interact with FA
that cause high-level resistance [6]). Third, antibiotics can
be enzymatically degraded or modified. Fourth, an organism
can evolve an altered metabolic pathway to circumvent the
drug-caused inhibition. To our knowledge, there are very
few examples in the literature of resistance mechanisms that
do not fall into these four categories.
Tetracyclin is a translation-inhibiting antibiotic for which
one of the resistance mechanism involves so-called ribosomal
protection proteins (RPPs; reviewed in [36]). Tetracycline
binds to 16 S rRNA close to the decoding centre, preventing
binding of aminoacyl-tRNA to the A site. The RPPs such as
Tet(M) and Tet(O) are sequence homologues of EF-G that
release tetracycline from the ribosome in a GTP-dependent
manner [37], probably by locally disturbing the rRNA struc-
ture of the binding site, as indicated by cryo-electron
microscopy [38].
Quinolones and fluroquinolones bind to DNA comple-
xes of DNA gyrase and topoisomerase IV, and trap enzyme
complexes with cleaved DNA. Pentapeptide-repeat protein
(PRP) MfpA in mycobacteria and the analogous Qnr
proteins in enterobacteria cause a low level of quinolone
resistance. These resistance proteins form DNA-mimicking
structures [39], which were suggested to destabilize the
drug-inhibited complexes and to cause release of the anti-
biotic and the DNA [40].
Thus, a fifth general resistance mechanism unifying the
tetracycline RPPs and the quinolone PRPs might be to
increase the off-rate of the antibiotic by binding to and alter-
ing the conformation of the target. If FusB were to act by a
similar mechanism, it would imply that FusB would increase
the off-rate of FA and/or of EF-G in the presence of FA. The
latter was demonstrated to occur on vacant ribosomes (lack-
ing mRNA and tRNAs), where FusB accelerated the
dissociation of EF-G in the presence as well as in the absence
of FA [34], suggesting that FusB acts according to the same
mechanism on programmed ribosomes in vivo.
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84.6. Suggested mechanisms of FusB action
FAbindstoapocketbetweendomainsI,IIandIIIofEF-Ginthe
post-translocational statewith GDP on the ribosome. Bystimu-
latingthereleaseofEF-G[34],FusBcanreleasethisinhibitionso
that the ribosome can accept a new aminoacylated tRNA or
split into subunits, allowing translation to proceed.
In our experiments, we demonstrate FusB-mediated rescue
at 1 mM concentration, but the concentration of FusB in S.
aureus under induced conditions remains unknown. The Kd
of the FusB–EF-G complex is around 60 nM [34], and EF-G
and ribosomes are present at roughly 1 mM concentration in
vivo, suggesting that all free EF-G may be bound to FusB.
Still, two scenarios are possible: FusB may cycle between
EF-G molecules or stay bound to EF-G during translation.
While fusA mutants typically have poor growth rate when
compared with wild-type and acquire secondary fitness-
compensatory mutations [17,41], expression of FusB or its
homologues FusC and FusD does not affect the growth rate
in the absence of FA [25], suggesting that these proteins do
not have a negative effect on EF-G activity. Thus, if FusB
stays bound to EF-G, the complex should have a similar
level of activity as the free EF-G.
Would an interaction of FusB with domain IV of EF-G be
compatible with ribosome binding? Apart from the terminal
helix, we do not know which parts of domain IV, and poss-
ibly of other domains, are involved in FusB binding. On the
ribosome, only the tip of EF-G domain IV makes contact
with mRNA, P-site tRNA and the decoding centre [6], and
the surface with the beta sheet (figure 4a) is accessible from
the outside, and potentially available for binding to FusB.
The terminal helix does not make any direct contact with
the ribosome in the FA-locked state. However, to reach this
helix when EF-G is bound to the ribosome, FusB would
need to insert between domain IV of EF-G and the P-site
tRNA, a space surrounded by 23 S rRNA helix 38, L11 and
L25. A recent docking experiment [34] suggests that FusB
binds to a surface of domains III and IV of EF-G that is inac-
cessible on the ribosome, which we consider unlikely, as FusB
can accelerate the release of EF-G [34].
From the present data, we thus propose two possible
mechanisms: (1) FusB binds to EF-G in the FA-locked state
and induces conformational changes that facilitate dis-
sociation of EF-G and FA; (2) the FusB–EF-G complex
performs translocation and recycling on the ribosome, but
FusB prevents EF-G from reaching the conformation to
which FA binds or prevents locking in the presence of FA.
The conformational changes needed for FA dissociation
could be on the inter-domain level or local changes in the
FA-binding site. There are several examples of fusA resistance
mutations that are predicted to cause resistance by affecting
the inter-domain arrangement in EF-G [10]. If FusB would
bind to EF-G using the beta sheet S3–S4–S5, as indicated
by chemical shift mapping [34], or the conserved loops at
the outer edge of the C-terminal domain, the rigid N-terminal
domain could provide a lever interacting with another part of
EF-G or with the ribosome to achieve conformational change
of EF-G. The distance between the terminal helix and FA is
roughly 40 A ˚ (pdb 2wri [6]), which would allow FusB to
bridge between the two relevant sites.
To further clarify the mechanism of FusB-mediated FA
resistance, we will pursue our biochemical studies, as well as
structural studies of the FusB–EF-G complex. Here, we have
solved the crystal structure of FusB, mapped the sequence
determinants for its recognition of EF-G, and monitored
FusB-dependent rescue of FA inhibition in translocation and
recycling, providing asolid foundationfor furtherexperiments.
5. Materials and methods
5.1. Sequence analysis
Sequence alignment was done using the CLUSTALW2
server [42].
5.2. Cloning of FusB
A single colony of S. aureus WBG157, pUB101 (gift from
D. Hughes), was grown in 15 ml Luria broth (LB) medium con-
taining 0.5 per cent glycine at 378C overnight without shaking.
The pelleted cells were resuspended in 100 ml lysis buffer
(20 mM Tris pH 7.5, 0.1 g ml
21 lysostaphin, 30 mg ml
21 lyso-
zyme, 3 mg ml
21 proteinase K) and incubated at 378C for 1 h.
Starting from the lysate, pUB101 was purified using the QIA-
prep Spin Miniprep kit (Qiagen). To obtain a FusB construct
with an N-terminal His-tag, the fusB gene was amplified by
PCR using PfuUltra high-fidelity DNA polymerase (forward
and reverse primers: 50-ATGGCTCATCATCATCATCATCAT
GGTATGAAGACAATGATTTATCCTCAC-30 and 50-CACA
AACATAGTTAATTCCTTAATCTAG-30, respectively) using
pUB101 as a template. The PCR product was cloned into
pEXP5-CT/TOPO (Invitrogen). The correctness of the pFusB-
SN construct was confirmed by sequencing.
5.3. FusB expression and purification
pFusB-SN was transformed into BL21(DE3) cells and plated
on a Luria agar (LA) plate containing 50 mgm l
21 ampicillin.
A single colony was added to LB medium with 50 mgm l
21
ampicillin and grown at 378C o/n. One litre of culture was
inoculated with 5 ml o/n culture and incubated at 100 r.p.m.
at 378C. One millimolar isopropyl b-D-1-thiogalactopyrano-
side (IPTG) was added at OD (600) of 0.5. After 5 h, the cells
were pelleted by centrifugation at 4000g for 30 min. The cell
pellet was resuspended in lysis buffer (50 mM Tris pH 7.5,
300 mM NaCl, 20 mM imidazole) supplemented with Com-
plete Mini EDTA-free protease inhibitor (Roche). The cells
were lysed by sonication and the debris was pelleted at 18
000 r.p.m. for 30 min. The supernatant was transferred into
an Econo-Pac gravity column (Bio-Rad) together with 2 ml
Ni Sepharose (GE Healthcare) and equilibrated at 48C for
30 min. The matrix was washed with wash buffer (50 mM
Tris pH 7.8, 600 mM NaCl, 20 mM imidazole) and FusB was
eluted in elution buffer (50 mM Tris pH 7.8, 300 mM NaCl,
400 mM imidazole) and further purified on a Hiload 16/60
Superdex75 column (GE Healthcare) equilibrated in gel fil-
tration buffer (20 mM Tris pH 7.8, 300 mM NaCl). The FusB
peak was concentrated to 16 mg ml
21 in a VIVASPIN 6
(Sartorius Stedim) with a membrane cut-off of 10000 D.
5.4. Crystallization
Initial screening of crystallization conditions was performed at
the High Throughput Crystallisation Laboratory, Grenoble,
France. Hits from the Index screen (Hampton Research) were
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9optimized by varying the pH and precipitant concentration.
Diffraction quality crystals were obtained using the hanging-
drop vapour diffusion method at 48C. The drops contained
2 ml protein solution and 2 ml reservoir solution (200 mM
(NH4)2SO4, 100 mM Bis–Tris pH 5.5, 18% (w/v) PEG3350).
Crystals grew to a size of 0.05   0.05   0.3 mm in two weeks
and were cryo-protected in reservoir solution supplemen-
ted with 20 per cent (v/v) glycerol, and vitrified in liquid
nitrogen. For the iodine derivative, crystals were soaked in
cryo-protectant solution including 1 M of NaI for 4 h.
A second crystal form was obtained by the same method
using a reservoir solution containing 200 mM (NH4)2SO4,
100 mM Mops-Tris pH 8.1and 25% (w/v) PEG3350. At this con-
dition, crystals grew to a size of 0.03   0.03   0.005 mm in one
month.
5.5. Structure determination
Native and derivative datasets of FusB crystals were collected
at beamlines ID23-1 and ID23-2 (ESRF, Grenoble) at 100 K.
The iodine SAD dataset was collected in six 608 wedges,
each collected from a new section of the elongated crystal.
Data were processed with the XDS package [43]. The crystals
belong to space group P21212; X-ray data statistics are sum-
marized in table 1. Nineteen iodine sites could be located in
SAD phasing using PHENIX [44] with a figure-of-merit
of 0.449. Automatic building of the structure containing
two FusB molecules in the asymmetric unit followed by
rebuilding against the high-resolution native data was
performed in PHENIX. Further cycles of manual building
were performed in COOT [45] and refined using PHENIX. The
final structure containing the complete FusB sequence
(except the His-tags and residues 172–183 in the B molecule)
was refined to Rwork 16.3 per cent and Rfree 20.2 per cent.
Data from the second crystal form were processed with the
XDS package [43] in space group P1. The structure was solved
by molecular replacement in PHASER [46] using the P21212 FusB
structure as search model. The asymmetric unit contained two
FusBmoleculesinsimilararrangementasintheP21212 crystals.
ThestructurecontainingthecompleteFusBsequenceexceptthe
His-tags, residues 176–179 in the A molecule, and residues
103–104, 174–181 and 213 in the B molecule, were refined to
Rwork 20.4 per cent and Rfree 25.4 per cent using PHENIX [44].
The qualityof the structures was assessed in PHENIX.T h er e f i n e -
ment statistics can be found in table 1. The refined coordinates
have been deposited in the protein data bank with accession
Table 1. Functional classiﬁcation of differentially expressed genes in Mtb HN878-infected rabbit lungs (percentage).
a
FusB1 FusB iodine FusB2
data collection statistics
beamline ID14-4 ID23-1 ID23-1
wavelength (A ˚) 0.9392 1.5498 0.9537
space group P21212 P21212 P1
cell dimensions
a, b, c (A ˚) 74.98, 122.28, 52.89 74.85, 120.60, 52.76 45.10, 47.61, 53.24
a, b, g (8) 90, 90, 90 90, 90, 90 89.76, 83.46, 85.76
resolution (A ˚)
a 48.58–1.65 (1.70–1.65) 50–2.5 (2.60–2.50) 50–2.30 (2.35–2.30)
Rmerge
b 8.7 (53.9) 6.9 (11.3) 7.3 (43.6)
kI/s(I)l 22.2 (4.0) 24.7 (15.4) 14.4
completeness (%) 98.1 (86.1) 97.8 (92.0) 94.5 (95.9)
redundancy 14.9 7.5 3.9
reﬁnement statistics
reﬂections (test set) 58 343 (2918) 23 932 (905)
number of protein atoms 3648 3439
number of waters 353 99
B-factor (A ˚2)
protein 27.7 48.3
waters 35.4 36.8
Rwork/Rfree (%) 16.3/20.2 20.4/25.4
RMSD from ideal bond length (A ˚) 0.011 0.018
RMSD from ideal bond angle (8) 0.873 1.605
Ramachandran plot
preferred (%) 98.9 97.3
allowed (%) 1.1 2.7
outliers (%) 0 0
aValues in parentheses represent the highest resolution bin.
bRmeas ¼
P
hkl N=½NðhklÞ 1  fg  
1=2 P
i IiðhklÞ ð IðhklÞÞ jj =
P
hkl
P
i IiðhklÞ:
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10numbers 4adn (P21212) and 4ado (P1). All structural figures
were prepared using PYMOL [47].
5.6. Cloning and preparation of hybrid elongation
factor G constructs
AllhybridEF-Gconstructsweremadebycloningtherespective
E. coli sequence into the vector pET30-Sa-EFG [48] by restric-
tion-free cloning [49]. First, the DNA sequence encoding the
desired E. coli domain(s) was amplified using a plasmid con-
struct of E. coli EF-G as template. The primers were designed
so that the resulting DNA fragment had the E. coli sequence
of choice flanked with extensions complementary to the
sequence around the insertion site in the vector with the S.
aureus EF-G encoding sequence (electronic supplementary
material, table S1). In a second, linear amplification reaction,
this DNA fragment was used as primer pair, and the pET30-
Sa-EFG vector was used as template. Construct pEFG-ECO1-
615_SAU604-674_ECO687 was done with two PCR products
introduced simultaneously into the vector [50]. All amplifica-
tions were done using PfuUltra (Stratagene). The resulting
DNA was treated with DpnI to digest the parental vector and
transformed into OneShot TOP10 Chemically Competent E.
coli (Invitrogen). The correctness of the hybrid EF-G constructs
was verified by DNA sequencing.
For expression, all hybrid EF-G plasmid constructs were
transformed into BL21(DE3) cells and plated on LA plates
containing 50 mgm l
21 kanamycin at 168C o/n. One litre cul-
tures in LB medium were inoculated with 5 ml o/n culture
and grown at 378C until OD(600) of 0.5. The cultures were
cooled before addition of 1 mM IPTG and further incubation
at 168C o/n. Purification was done using the same protocol as
for FusB but using EF-G wash buffer (50 mM Tris–HCl,
200 mM NaCl, 20 mM imidazole, 5 mM 2-mercaptoethanol,
pH 7.5) and EF-G elution buffer (50 mM Tris–HCl, 200 mM
NaCl, 500 mM imidazole, 5 mM 2-mercaptoethanol, pH7.5).
Size-exclusion chromatography was performed using a
HiLoad 16/60 Superdex200 column (GE Healthcare).
5.7. Size-exclusion binding assay
Samples of 2 nmol EF-G (wild-type or hybrid constructs) with
or without 4 nmol FusB were prepared in 100 ml gel filtration
buffer and loaded on a Hiload 10/300 Superdex200 column
(GE Healthcare) equilibrated in the same buffer. Protein con-
centration was determined based on A280 and theoretical
extinction coefficients (47790 M
21 cm
21 for S. aureus EF-G
and 58460 M
21 cm
21 for E. coli EF-G; varying between these
two values for the hybrid constructs). All constructs including
domain III from S. aureus were aggregation-prone and had to
be used fresh from gel filtration.
5.8. Components for biochemical experiments
All translation components except EF-G were from E. coli. EF-G
from S. aureus was overexpressed and purified as described
[10]. The MRE600 ribosomes, His-tagged E. coli translation fac-
tors, XR7 fMet-Phe-Phe-stop (MFF) mRNA and fMet-tRNA
fMet
werepurifiedasdescribedearlier[33,51].Theexperimentswere
performed in HEPES polymix buffer (pH 7.5) at 378C( f o r
details see [33]). Additionally, the reactions contained energy
components such as ATP (1 mM), GTP (1 mM),
phosphoenolpyruvate (PEP, 10 mM), pyruvate kinase (PK,
50 mgm l
21) and myokinase (MK, 2 mgm l
21). FA was from
Leo Pharma (Denmark). tRNA
Phewas purchased from Chemi-
cal Block (Moscow, Russia). PEP, PK, MK and non-radioactive
amino acids were from Sigma-Aldrich. Radioactive amino
acids and nucleotide triphosphates were from GE Healthcare.
5.9. FusB action in a reconstituted transcription–
translation system
Staphylococcus aureus or E. coli EF-G were used in a reconsti-
tuted transcription–translation system composed of E. coli
components for synthesis of a 593 amino acid construct of
firefly luciferase [33]. This system was used to study the
effect of FA (10–50 mM) and FusB (1 mM) in various combi-
nations. To study single-round synthesis of luciferase
involving only the elongation function of EF-G, RRF was
excluded from the reaction mix.
5.10. Tripeptide formation assay
The initiation complexes (IM) were formed by incubating 70S
ribosomes (1 mM), [
3H]fMet-tRNA
fMet (1 mM), XR7 mRNA
fMet-Phe-Phe-stop (MFF) (4 mM), initiation factors: IF1, IF2,
IF3(1 mMeach)at378Cfor15 min.Anelongationmix(EM)con-
taining EF-Tu (10 mM), EF-Ts (5 mM), phenyl alanine (200 mM),
tRNA
Phe (5 mM), tRNA
Phe-synthetase (0.2 units ml) and EF-G
(5 mM), without or with FA (150 mM) and FusB (1 mM) was
also incubated at 378C for 15 min. Equal volumes of IM and
EM were mixed by hand and the reaction was quenched after
10 s by adding formic acid (17% final concentration). The ribo-
some-containing pellet was dissolved in potassium hydroxide,
and the amount of MF di- and MFF tripeptide was analysed
with reversed-phase high-performance liquid chromatography
by comparing the respective peaks with the peak of [
3H]fMet.
All experiments were performed in triplicates.
5.11. Ribosome recycling assay
A post-termination complex was formed by incubating 70S
ribosomes (0.5 mM), XR7 MFF mRNA (2 mM) and tRNA
Phe
(3 mM) at 378C for 20 min. To this complex, a mix containing
RRF (10 mM), EF-G (5 mM) and IF3 (2 mM) without or with
FA (10 mM) and FusB (1 mM) preincubated at 378Cw a s
rapidly added in a stopped flow apparatus. The kinetics of
splitting of 70S ribosomes into subunits was monitored by
measuring Rayleigh light scattering as described [52].
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